NASDAQ:HZNP - Horizon Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Horizon Therapeutics PLC Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $34.06 -1.07 (-3.05 %) (As of 02/27/2020 04:00 PM ET) Add Compare Today's Range$33.84Now: $34.06▼$35.5650-Day Range$33.88MA: $36.19▼$38.5652-Week Range$22.69Now: $34.06▼$39.10Volume2.49 million shsAverage Volume1.51 million shsMarket Capitalization$6.38 billionP/E Ratio92.05Dividend YieldN/ABeta1.07 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Horizon Therapeutics Public Limited Company, a biopharmaceutical company, focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. Its orphan and rheumatology marketed medicines include KRYSTEXXA, a medicine for the treatment of uncontrolled gout; RAVICTI for use as a nitrogen-binding agent for chronic management of adult and pediatric patients; PROCYSBI for nephropathic cystinosis, a rare and life-threatening metabolic disorder; ACTIMMUNE for chronic granulomatous disease; RAYOS for the treatment of multiple conditions, rheumatoid arthritis; BUPHENYL tablets for oral administration and BUPHENYL powder for oral, nasogastric, or gastrostomy tube administration; and QUINSAIR, a formulation of the antibiotic drug levofloxacin for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryPharmaceuticals SectorMedical Current SymbolNASDAQ:HZNP Previous Symbol CUSIP44047T10 CIK1492426 Webhttp://www.horizontherapeutics.com/ Phone011-353-1772-2100Debt Debt-to-Equity Ratio0.87 Current Ratio2.33 Quick Ratio2.23Price-To-Earnings Trailing P/E Ratio92.05 Forward P/E Ratio21.97 P/E Growth1.43 Sales & Book Value Annual Sales$1.21 billion Price / Sales5.28 Cash Flow$3.98 per share Price / Cash Flow8.56 Book Value$6.29 per share Price / Book5.41Profitability EPS (Most Recent Fiscal Year)$1.83 Net Income$-74,190,000.00 Net Margins5.25% Return on Equity27.71% Return on Assets10.07%Miscellaneous Employees1,000 Outstanding Shares187,302,000Market Cap$6.38 billion Next Earnings Date5/13/2020 (Estimated) OptionableOptionable Receive HZNP News and Ratings via Email Sign-up to receive the latest news and ratings for HZNP and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:HZNP Rates by TradingView Horizon Therapeutics (NASDAQ:HZNP) Frequently Asked Questions What is Horizon Therapeutics' stock symbol? Horizon Therapeutics trades on the NASDAQ under the ticker symbol "HZNP." How were Horizon Therapeutics' earnings last quarter? Horizon Therapeutics PLC (NASDAQ:HZNP) issued its quarterly earnings data on Wednesday, February, 26th. The biopharmaceutical company reported $0.56 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.42 by $0.14. The biopharmaceutical company had revenue of $363.50 million for the quarter, compared to analyst estimates of $349.25 million. Horizon Therapeutics had a return on equity of 27.71% and a net margin of 5.25%. The business's quarterly revenue was up 2.3% compared to the same quarter last year. During the same quarter last year, the company posted $0.67 earnings per share. View Horizon Therapeutics' Earnings History. When is Horizon Therapeutics' next earnings date? Horizon Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, May 13th 2020. View Earnings Estimates for Horizon Therapeutics. What guidance has Horizon Therapeutics issued on next quarter's earnings? Horizon Therapeutics issued an update on its FY 2020 Pre-Market earnings guidance on Wednesday, February, 26th. The company provided EPS guidance of for the period. The company issued revenue guidance of $1.4-1.42 billion, compared to the consensus revenue estimate of $1.39 billion. What price target have analysts set for HZNP? 13 equities research analysts have issued 12 month price objectives for Horizon Therapeutics' stock. Their forecasts range from $27.00 to $49.00. On average, they expect Horizon Therapeutics' stock price to reach $38.92 in the next twelve months. This suggests a possible upside of 14.3% from the stock's current price. View Analyst Price Targets for Horizon Therapeutics. What is the consensus analysts' recommendation for Horizon Therapeutics? 13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Horizon Therapeutics in the last year. There are currently 2 hold ratings and 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Horizon Therapeutics. What are Wall Street analysts saying about Horizon Therapeutics stock? Here are some recent quotes from research analysts about Horizon Therapeutics stock: 1. According to Zacks Investment Research, "Horizon’s efforts to develop its pipeline are impressive. The company's BLA for teprotumumab was accepted by the FDA in September. The FDA set an action date of Mar 8, 2020. A potential approval will significantly boost the company’s performance. The company also initiated the MIRROR study on Krystexxa in the second quarter. The study is designed to support the potential for registration of the drug. Horizon expects continued strong growth for Krystexxa, going forward, and teprotumumab, beginning 2020. Shares of the company have outperformed the industry in the past year. However, it faces intense competition from pharmaceutical and biotechnology companies and universities. Estimates are stable ahead of Q3 results." (10/29/2019) 2. Cantor Fitzgerald analysts commented, ". We have updated our financial model to include: 1) HZNP’s recent equity offering, and 2) sales for teprotumumab starting in 2020, given the positive Phase 3 results earlier this year. Both the equity raise and positive Phase 3 data support our OW rating on HZNP shares. Therefore, we are raising our PT to $32 from $26. The increase in our PT is driven by upward earnings revisions for 2020+ given we now include risk adjusted sales for teprotumumab in our financial model." (4/2/2019) Has Horizon Therapeutics been receiving favorable news coverage? News headlines about HZNP stock have been trending somewhat negative recently, according to InfoTrie. InfoTrie ranks the sentiment of media coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Horizon Therapeutics earned a news sentiment score of -1.7 on InfoTrie's scale. They also gave press coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the next several days. View News Stories for Horizon Therapeutics. Who are some of Horizon Therapeutics' key competitors? Some companies that are related to Horizon Therapeutics include Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Pfizer (PFE), AbbVie (ABBV), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Allergan (AGN), Mylan (MYL), Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ), The Medicines (MDCO), Nektar Therapeutics (NKTR), Pacira Biosciences (PCRX) and Corcept Therapeutics (CORT). What other stocks do shareholders of Horizon Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Horizon Therapeutics investors own include Opko Health (OPK), Alibaba Group (BABA), Netflix (NFLX), Gilead Sciences (GILD), TherapeuticsMD (TXMD), NVIDIA (NVDA), Allergan (AGN), AbbVie (ABBV), Bank of America (BAC) and Celgene (CELG). Who are Horizon Therapeutics' key executives? Horizon Therapeutics' management team includes the folowing people: Mr. Timothy P. Walbert, Chairman, Pres & CEO (Age 52)Mr. Paul W. Hoelscher, Exec. VP & CFO (Age 54)Dr. Shao-Lee Lin M.D., Ph.D., Exec. VP, Head of R&D and Chief Scientific Officer (Age 52)Mr. Barry J. Moze, Exec. VP & Chief Admin. Officer (Age 65)Mr. Robert F. Carey, Exec. VP & Chief Bus. Officer (Age 60) Who are Horizon Therapeutics' major shareholders? Horizon Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (5.39%), William Blair Investment Management LLC (4.73%), FMR LLC (3.49%), Janus Henderson Group PLC (3.14%), State Street Corp (1.39%) and Geode Capital Management LLC (1.13%). Company insiders that own Horizon Therapeutics stock include Brian K Beeler, Geoffrey M Curtis, Irina Konstantinovsky, James Samuel Shannon, Jeff Kent, Paul W Hoelscher, Timothy P Walbert and Vikram Karnani. View Institutional Ownership Trends for Horizon Therapeutics. Which major investors are selling Horizon Therapeutics stock? HZNP stock was sold by a variety of institutional investors in the last quarter, including Eagle Asset Management Inc., Jennison Associates LLC, Acadian Asset Management LLC, Alyeska Investment Group L.P., Rhenman & Partners Asset Management AB, Russell Investments Group Ltd., Schonfeld Strategic Advisors LLC and JW Asset Management LLC. Company insiders that have sold Horizon Therapeutics company stock in the last year include Brian K Beeler, Geoffrey M Curtis, Irina Konstantinovsky, James Samuel Shannon, Jeff Kent, Paul W Hoelscher, Timothy P Walbert and Vikram Karnani. View Insider Buying and Selling for Horizon Therapeutics. Which major investors are buying Horizon Therapeutics stock? HZNP stock was acquired by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Bank of Montreal Can, Renaissance Technologies LLC, Victory Capital Management Inc., Victory Capital Management Inc., William Blair Investment Management LLC, First Trust Advisors LP and Standard Life Aberdeen plc. View Insider Buying and Selling for Horizon Therapeutics. How do I buy shares of Horizon Therapeutics? Shares of HZNP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Horizon Therapeutics' stock price today? One share of HZNP stock can currently be purchased for approximately $34.06. How big of a company is Horizon Therapeutics? Horizon Therapeutics has a market capitalization of $6.38 billion and generates $1.21 billion in revenue each year. The biopharmaceutical company earns $-74,190,000.00 in net income (profit) each year or $1.83 on an earnings per share basis. Horizon Therapeutics employs 1,000 workers across the globe.View Additional Information About Horizon Therapeutics. What is Horizon Therapeutics' official website? The official website for Horizon Therapeutics is http://www.horizontherapeutics.com/. How can I contact Horizon Therapeutics? Horizon Therapeutics' mailing address is 1 BURLINGTON ROAD CONNAUGHT HOUSE 1ST FLOOR, DUBLIN L2, D04 C5Y6. The biopharmaceutical company can be reached via phone at 011-353-1772-2100 or via email at [email protected] MarketBeat Community Rating for Horizon Therapeutics (NASDAQ HZNP)Community Ranking: 3.3 out of 5 ( )Outperform Votes: 811 (Vote Outperform)Underperform Votes: 413 (Vote Underperform)Total Votes: 1,224MarketBeat's community ratings are surveys of what our community members think about Horizon Therapeutics and other stocks. Vote "Outperform" if you believe HZNP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe HZNP will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/27/2020 by MarketBeat.com StaffFeatured Article: How to Invest in an Index Fund
